Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study
Stereotactic ablative body radiotherapy(SABR) is increasingly being used to treat oligometastatic cancers, but high-level evidence to provide a basis for policymaking is scarce. SABR was commissioned by NHS England in March 2020 as a treatment option. Between June 15, 2015, and Jan 30, 2019, 1422 patients were recruited from 17 hospitals in England. The median age of the patients was 69 years and the most common tumor was prostate cancer.
